Biobanks are specialized facilities that store and manage biological samples, such as tissues, blood, cells, DNA, and other bodily fluids, along with associated clinical and demographic data. These repositories play a crucial role in biomedical research, translational medicine, and personalized healthcare by providing researchers, clinicians, and pharmaceutical companies with access to high-quality biospecimens for various applications.

Biobanks support basic, translational, and clinical research by providing researchers with access to well-characterized biospecimens and associated data. These resources facilitate studies aimed at understanding the molecular mechanisms of diseases, identifying biomarkers for early detection and diagnosis, elucidating disease progression, and developing new therapeutic interventions. Biobanks contribute to the drug discovery and development process by supplying researchers and pharmaceutical companies with the biological materials needed to identify and validate potential drug targets, evaluate drug efficacy and safety, conduct preclinical and clinical trials, and assess drug responses in patient populations. In terms of revenue, the global biobanks market was worth US$ 81.22 Bn in 2023, anticipated to witness CAGR of 11.1% During 2024 – 2034.

Global Biobanks Market Dynamics

Increasing Demand for Personalized Medicine: The growing emphasis on personalized medicine and precision healthcare has fuelled the demand for high-quality biospecimens and associated clinical data for research and therapeutic development. Biobanks play a crucial role in collecting, storing, and distributing biological samples and related information to support translational research, biomarker discovery, and drug development efforts aimed at delivering targeted therapies and interventions tailored to individual patient profiles.

Rapid Advancements in Biomedical Research: Technological advancements in genomics, proteomics, and other omics disciplines have accelerated biomedical research initiatives focused on understanding the molecular basis of diseases and identifying potential therapeutic targets. Biobanks serve as valuable repositories of well-characterized biospecimens and longitudinal health data, enabling researchers to conduct large-scale epidemiological studies, genome-wide association studies (GWAS), and multi-omics analyses to elucidate disease mechanisms, identify biomarkers, and develop novel diagnostic tools and treatments.

Equipment has Gained Popularity in the Recent Years and Has garnered major market share in the Global Biobanks Market During the Forecast Period (2024 – 2034).

Biobanks require specialized equipment for sample processing tasks such as centrifugation, aliquoting, Labeling, and preservation. High-throughput automated systems and robotic platforms enhance the efficiency and accuracy of sample handling procedures, allowing biobanks to process large volumes of samples quickly and consistently. Demand for equipment that enables streamlined sample processing workflows is driven by the need to optimize resource utilization, minimize manual errors, and accelerate sample turnaround times. Proper storage conditions are critical for maintaining sample integrity and stability over time. Biobanks invest in equipment such as ultra-low temperature freezers, cryogenic storage systems, and automated sample retrieval systems to ensure optimal storage conditions for various sample types, including tissues, blood, cells, and DNA. Demand for reliable and energy-efficient storage solutions is driven by the need to preserve sample quality, minimize sample degradation, and comply with regulatory requirements governing sample storage and tracking.

By Sample Type Blood Products Segment had the Highest Share in the Global Biobanks Market in 2023.

The Blood Product segment dominated the global Biobanks market, in terms of revenue and is estimated to sustain its dominance over the forecast period.  Blood products obtained from biobanks are essential for various clinical applications, including transfusions for patients undergoing surgeries, cancer treatments, organ transplants, and management of blood disorders such as anaemia and haemophilia. The availability of a diverse range of blood products ensures that healthcare providers can meet the needs of patients with different medical conditions. Biobanks serve as valuable resources for biomedical research aimed at understanding the physiology of blood, identifying disease biomarkers, developing new diagnostic tests, and discovering novel therapies. Blood samples stored in biobanks are used in studies investigating the genetic basis of diseases, pharmacogenomics, and population health research, among other areas. The demand for blood products from biobanks is driven by the need for high-quality samples to support research initiatives.

By End User Pharmaceutical & Biotechnology Companies and CROs has the Highest Share in the Global Biobanks Market in 2023.

Pharmaceutical and biotechnology companies conduct extensive research and development (R&D) activities to discover and develop new drugs, therapies, and medical products. Biobanks provide these companies with access to high-quality human biological samples, including tissues, blood, cells, and DNA, which are essential for conducting preclinical studies, biomarker discovery, target validation, and clinical trials. The availability of well-characterized and ethically sourced samples from diverse populations is crucial for accelerating the drug development process. With the rise of precision medicine approaches, pharmaceutical and biotechnology companies are increasingly focusing on developing targeted therapies and personalized treatments tailored to individual patients. Biobanks play a critical role in supporting precision medicine initiatives by providing access to longitudinal patient samples, clinical data, and genetic information. By analyzing these resources, companies can identify genetic markers, biomarkers, and therapeutic targets associated with specific diseases or patient subpopulations, leading to the development of more effective and personalized treatments.

North America has garnered major market share in 2023 accounting for ~43.5% in the global biobanks market. North America is home to numerous pharmaceutical, biotechnology, and research institutions that are actively engaged in drug discovery, development, and clinical research. Biobanks play a crucial role in supporting these efforts by providing researchers with access to high-quality biological samples, such as tissue, blood, and DNA, along with associated clinical and demographic data. The adoption of precision medicine approaches, which aim to tailor medical treatments to individual patients based on their genetic makeup, is driving the demand for biobanks in North America. Biobanks serve as repositories of diverse biological samples and molecular data, enabling researchers and clinicians to study the genetic basis of diseases, identify biomarkers, and develop personalized therapies. The rapid advancements in genomics, proteomics, and other omics technologies have generated vast amounts of biological data that require comprehensive storage and management solutions. Biobanks provide a centralized platform for storing, cataloging, and sharing biological samples and associated data, facilitating collaborative research and data-driven discoveries.

Competitive Landscape: Global Biobanks Market:

• Avantor Inc.
• Azenta Inc
• Becton Dickinson and Company
• Cryoport Inc.
• Hamilton Company
• Merck & Co., Inc.
• PHC Holdings Corporation
• Qiagen N.V.
• Tecan Trading AG
• Thermo Fisher Scientific, Inc.
• Other Industry Participants

Global Biobanks Market: Key Takeaway

Global Biobanks Market

By Product & Service

• Equipment
  • Storage Equipment
  • Sample Analysis Equipment
  • Sample Processing Equipment
  • Sample Transport Equipment
• Consumables
  • Storage Consumables
  • Analysis Consumables
  • Processing Consumables
  • Collection Consumables
• Services
  • Storage Services
  • Processing Services
  • Transport Services
  • Supply Services
• Software

By Sample Type

• Blood Products
• Human Tissues
• Cell Lines
• Nucleic Acids
• Biological Fluids
• Human Waste product

By Storage Type

• Manual Storage
• Automated Storage

By Ownership

• Universities
• National/ Regional agencies
• Non-Profit Organization
• Private organization

By Application

• Regenerative Medicine
• Life Science Research
• Clinical Research

By End-User

• Pharmaceutical & Biotechnology Companies and CROs
• Academic & Research Institutes
• Hospitals

By Region

• North America (U.S., Canada, Mexico, Rest of North America)
• Europe (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe
• Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific
• Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa)
• Latin America (Brazil, Argentina, Rest of Latin America)

Report Layout:

Table of Contents

.